Denali Therapeutics Inc (DNLI)
17.14
+0.33
(+1.96%)
USD |
NASDAQ |
May 03, 16:00
17.14
0.00 (0.00%)
After-Hours: 20:00
Denali Therapeutics Revenue (Quarterly)
Revenue (Quarterly) Chart
Historical Revenue (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2023 | 1.267M |
| June 30, 2023 | 294.12M |
| March 31, 2023 | 35.14M |
| December 31, 2022 | 10.28M |
| September 30, 2022 | 3.559M |
| June 30, 2022 | 52.48M |
| March 31, 2022 | 42.14M |
| December 31, 2021 | 12.51M |
| September 30, 2021 | 5.285M |
| June 30, 2021 | 22.94M |
| March 31, 2021 | 7.923M |
| December 31, 2020 | 316.82M |
| Date | Value |
|---|---|
| September 30, 2020 | 9.393M |
| June 30, 2020 | 5.847M |
| March 31, 2020 | 3.604M |
| December 31, 2019 | 4.672M |
| September 30, 2019 | 13.60M |
| June 30, 2019 | 4.197M |
| March 31, 2019 | 4.205M |
| December 31, 2018 | 125.68M |
| September 30, 2018 | 1.195M |
| June 30, 2018 | 1.648M |
| March 31, 2018 | 0.641M |
Revenues Definition
Revenues measure the total amount of value that a company brings in during a certain period. This is also considered the "top-line" of the income statement. Revenues are used for all operating expenses as well as other line items which eventually lead to the net income for the company. Revenue is an extremely important metric when analyzing a company. A company with efficient margins is able to turn revenues into the most net income.
Revenue (Quarterly) Range, Past 5 Years
1.267M
Minimum
Sep 2023
316.82M
Maximum
Dec 2020
46.99M
Average
9.838M
Median
Revenue (Quarterly) Benchmarks
| Halozyme Therapeutics Inc | 230.04M |
| AIM ImmunoTech Inc | 0.065M |
| Perspective Therapeutics Inc | -5.239M |
| Protalix BioTherapeutics Inc | 10.49M |
| Armata Pharmaceuticals Inc | -- |
Revenue (Quarterly) Related Metrics
| Net Income (Quarterly) | -119.47M |
| Total Expenses (Quarterly) | 132.57M |
| EPS Diluted (Quarterly) | -0.86 |
| Enterprise Value | 1.409B |
| Earnings Yield | -6.30% |
| Normalized Earnings Yield | -5.659 |